Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced it will release its fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company's senior management will host a webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update. The webcast will be accessible through the company's investor relations website, with a replay available for at least 14 days following the live presentation.
Revolution Medicines (Nasdaq: RVMD), una azienda di oncologia in fase avanzata focalizzata sullo sviluppo di terapie mirate per i tumori dipendenti da RAS, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 mercoledì 26 febbraio 2025, dopo la chiusura del mercato. Il senior management dell'azienda ospiterà un webcast alle 16:30 ET (13:30 PT) per discutere i risultati finanziari e fornire un aggiornamento aziendale. Il webcast sarà accessibile attraverso il sito web delle relazioni con gli investitori dell'azienda, con una registrazione disponibile per almeno 14 giorni dopo la presentazione dal vivo.
Revolution Medicines (Nasdaq: RVMD), una empresa de oncología en etapa avanzada centrada en desarrollar terapias dirigidas para cánceres adictos a RAS, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el miércoles 26 de febrero de 2025, después del cierre del mercado. La alta dirección de la empresa llevará a cabo un webcast a las 4:30 p.m. ET (1:30 p.m. PT) para discutir los resultados financieros y ofrecer una actualización corporativa. El webcast será accesible a través del sitio web de relaciones con inversores de la empresa, con una repetición disponible durante al menos 14 días después de la presentación en vivo.
Revolution Medicines (Nasdaq: RVMD)는 말기 임상 종양학 회사로 RAS 의존성 암을 위한 표적 치료제를 개발하는 데 주력하고 있으며, 2025년 2월 26일 수요일 시장 종료 후 2024년 4분기 및 연간 재무 결과를 발표할 것이라고 발표했습니다. 회사의 고위 경영진은 동부 표준시 기준 오후 4시 30분(태평양 표준시 기준 오후 1시 30분)에 재무 결과를 논의하고 기업 업데이트를 제공하기 위해 웹캐스트를 개최할 것입니다. 웹캐스트는 회사의 투자자 관계 웹사이트를 통해 접근할 수 있으며, 라이브 프레젠테이션 이후 최소 14일 동안 다시 볼 수 있습니다.
Revolution Medicines (Nasdaq: RVMD), une entreprise d'oncologie en phase avancée axée sur le développement de thérapies ciblées pour les cancers dépendants de RAS, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année 2024 le mercredi 26 février 2025, après la clôture du marché. La direction de l'entreprise animera un webinaire à 16h30 ET (13h30 PT) pour discuter des résultats financiers et fournir une mise à jour sur l'entreprise. Le webinaire sera accessible via le site Web des relations investisseurs de l'entreprise, avec une rediffusion disponible pendant au moins 14 jours après la présentation en direct.
Revolution Medicines (Nasdaq: RVMD), ein unternehmen der späten klinischen Onkologie, das sich auf die Entwicklung gezielter Therapien für RAS-abhängige Krebserkrankungen konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 am Mittwoch, den 26. Februar 2025, nach Börsenschluss veröffentlichen wird. Das Senior Management des Unternehmens wird um 16:30 Uhr ET (13:30 Uhr PT) ein Webcast veranstalten, um die Finanzergebnisse zu erörtern und ein Unternehmensupdate zu geben. Der Webcast wird über die Investor-Relations-Website des Unternehmens zugänglich sein, mit einer Wiederholung, die mindestens 14 Tage nach der Live-Präsentation verfügbar sein wird.
- None.
- None.
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
When will Revolution Medicines (RVMD) report Q4 and full year 2024 earnings?
What time is the RVMD Q4 2024 earnings call?
How can investors access RVMD's Q4 2024 earnings webcast?
How long will RVMD's Q4 2024 earnings webcast replay be available?
